The British Association for the Study of the Liver is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions.
The British Association for the Study of the Liver aims to disseminate research findings and clinical expertise, to promote opportunities for collaboration in liver research, to provide a voice that can advise and interact with the media and advises policymakers.
Dr Luke Boulter (centre) winner of the BASL Dame Sheila Sherlock Prize Lecture in 2015, he is pictured here with his team David Wilson (left) and Ronan Mellin (right). The Prize Lecture took place this year at the Basic Science Retreat where Dr Boulter was presented with a crystal award and £1,000.
Dr Tom Bird winner of the BASL Andy Burroughs Young Investigator Award 2015. This is a new award given in honour of the late Professor Andrew Burroughs. Dr Bird presented a 30 minute lecture at the BLTG Meeting and was awarded a crystal award and £1,000.
The BASL Annual Meeting is the highlight of the BASL calendar and the main liver meeting in the UK. Join us in Manchester from 7 - 9 September. Participating at our conference provides a unique opportunity to be part of this exciting and vibrant event.
Find out more
Find out more about the work of our committee sub-groups and forums by clicking the logos below. These include The British Viral Hepatitis Group, British Association for the Study of the Liver Nurse Forum and the British Liver Transplant Group.
The British Viral Hepatitis aims to improve the management and study of patients with chronic viral liver disease, bringing together UK hepatologists, gastroenterologists, infectious disease physicians, virologists and interested epidemiologists.
British Association for the Study of the Liver Nurse Forum is a professional nursing organisation aiming to develop knowledge and understanding of liver disease, in order to improve the quality of patient care.
The BLTG (British Liver Transplant Group) was launched in 2014 to represent the professional interests of liver transplantation in the UK and promote strategic and academic development.
BASL ANNUAL MEETING, BLTG Transplant Meeting & BASLNF Meeting 2016
Manchester Central, 6-9 September
FIND OUT ALL OF THE INFORMATION BY VISITING OUR ANNUAL MEETING WEBSITE - CLICK HERE.
BASL is a multi-disciplinary society with around 850 members composed of interested individuals from clinical medicine, clinical and basic research and allied professions. Your Annual subscription is used to organise the Annual Meeting held each September.
Members of BASL receive the following benefits:
- discounted registration rates for the annual meeting and other relevant meetings
- eligibility for the BASL Travel Awards (for members below status of Senior Lecturer or Consultant to allow presentation of high-quality UK liver research at International meetings, including the American Association for the Study of Liver Disease)
- eligibility for the prestigious Dame Sheila Sherlock Award (to an emerging researcher in the field of liver disease, for members below status of Senior Lecturer or consultant). Applications are usually submitted to the BASL Committee three months prior to the annual meeting - details are announced.
Click here to find out more about joining us.
New evidence suggests that sleeping for a longer time at night may slightly increase the risk of non-alcoholic fatty liver disease (NAFLD) in middle-aged and elderly people.
A total of 8,965 NAFLD-free subjects with a mean age of 61.6 who had enrolled in the Chinese Dongfeng-Tongji cohort study at baseline were divided into five groups dependent on their sleep duration: under six hours, six to seven hours, seven to eight hours, eight to nine hours, and nine hours or more.
During five years of follow-up, 2,197 participants were newly diagnosed as NAFLD. Compared with those reported seven to eight hours of night-time sleep, the multivariable-adjusted odds ratios were 1.21 for those who slept eight to night hours and 1.31 for those who slept over nine hours. However, no significant association was found with short nightly sleep duration, i.e., under seven hours.
The effect of long night-time sleep on the risk of incident NAFLD was attenuated greatly by body mass index in men.
Night-time sleep duration and risk of nonalcoholic fatty liver disease: the Dongfeng-Tongji prospective study. Liu C, Zhong R, Lou J et al. Ann Med. 2016 Jun 21:1-9. [Epub ahead of print]
People who received rabbit antithymocyte globulin induction before liver transplantation had lower rejection rates and improved patient and graft survival than those receiving interleukin 2 receptor blocker.
This was the finding of a retrospective analyses using the University of Washington [Seattle] Transplant Database from 2005 to 2012 for adult primary liver transplant patients. Maintenance immunosuppressive agents were tacrolimus or tacrolimus-mycophenolate mofetil. Among 595 patients, 322 received rabbit antithymocyte globulin and 273 received interleukin 2 receptor blocker.
Acute cellular rejection was higher in those who received interleukin 2 receptor blocker than in those who received rabbit antithymocyte globulin (27% versus 18%).
Both patient survival at one year (95% versus 90%), three years (92% versus 87%), and five years (86% versus 80%) and graft survival at one year (93% versus 88%), three years (90% versus 86%), and five years (83% versus 78%) were superior with rabbit antithymocyte globulin than with the interleukin 2 receptor blocker.
In patients with HCV, the type of induction therapy did not have any effect on the timing of HCV recurrence. At one year after transplant, 33.3% in the rabbit antithymocyte globulin group had grade three to four inflammation and 10.2% had stage three to four fibrosis, compared with 16.8% and 4.8% in the interleukin 2 receptor blocker group.
Female recipient, Model for End-Stage Liver Disease score, hepatocellular carcinoma, and high preoperative serum creatinine levels were associated with less favourable patient and graft survival.
Superior patient and graft survival in adult liver transplant with rabbit antithymocyte globulin induction: experience with 595 patients. Montenovo MI, Jalikis FG, Li M et al. Exp Clin Transplant. 2016 Jun 15 [Epub ahead of print]
Several drugs used to treat liver disease, including classic and new direct-acting antivirals, may have neurologic complications.
This was the final conclusion of a review by neurologists from the University of Lisbon, who point out that type A hepatic encephalopathy (HE), which occurs in acute liver failure, is a neurologic emergency. They also said multiple measures should be taken to prevent and treat cerebral oedema.
In Type C HE, which occurs in chronic liver disease, management should be aimed at correcting precipitant factors and hyperammonemia. There is an increasing spectrum of drug treatments available to minimize ammonia toxicity.
Acquired hepatocerebral degeneration is a rare complication of the chronic form of HE, with typical clinical and brain MRI findings, whose most effective treatment is liver transplantation. Epilepsy is frequent and of multifactorial cause in patients with hepatic disease, and careful considerations should be made regarding choice of the appropriate anti-epileptic drugs.
Several mechanisms increase the risk of stroke in hepatic disease, but many of the drugs used to treat and prevent stroke are contraindicated in severe hepatic failure.
HCV increases the risk of ischemic stroke. Hemorrhagic stroke is more frequent in patients with liver disease of alcoholic etiology. Viral hepatitis is associated with a wide range of immune-mediated complications, mostly in the peripheral nervous system, which respond to different types of immunomodulatory treatment.
Management of neurologic manifestations in patients with liver disease. Ferro JM, Viana P, Santos P et al. Curr Treat Options Neurol. 2016 Aug;18(8):37
NICE are looking for Topic experts to join their updates committee in updating the Alcohol use disorder: diagnosis and management of physical complications guideline.
They need both lay members (people using services, family members and carers, and members of the public and community or voluntary sector) and people with a professional or practitioner background in the topic.
The update will look at the following:
• In patients with acute alcohol-related hepatitis, what is the safety and efficacy of corticosteroids versus placebo?
They are therefore seeking to recruit the following experts:
• 3 x Hepatologists/Physicians
• 1 x Lay member
• 1 x Nurse specialist
• 1 x Pharmacist
Both adverts will close 5pm on Wednesday 20th July 2016.
Please note that the key dates for meetings that must be attended are included in the advert – please take these into consideration when applying.
Submit your application for the Dame Sheila Sherlock Research Prize – deadline 09:00 hrs Monday 27th June 2016.
One of the highlights of the annual meeting this prize is awarded annually to recognise the enormous contribution of Dame Sheila Sherlock to the development of Hepatology as a discipline in its own right. In keeping with Dame Sheila’s enthusiasm for fostering young researchers, this eponymous research prize is awarded to young investigators without substantive posts in either medicine or science for their research contributions in the field of Hepatology.
The winner of the award will deliver a 20 minute lecture presenting their research during the Annual Meeting on Thursday 8th September 2016. This year the prize is free registration to the meeting, a place at the Annual Dinner and £1,000.
To apply, please send one A4 sheet outlining the research and another A4 sheet detailing the related publications.
Please send submissions to firstname.lastname@example.org before the deadline of 09.00hrs Monday 27th June 2016.
Submit your application for the Andy Burroughs Young Investigator Award - Deadline Monday 8th August 2016
The Andy Burroughs Young Investigator Award will take place during the BLTG Transplant Day. The awardee will deliver a 30 minute lecture presenting their research on Tuesday 6th September. This prize is awarded to young investigators, scientific or clinical, who are in training or within 2 years of taking up consultant positions (or equivalent).
The awardee will receive free registration to the meeting and £1,000.
To apply, please send one A4 sheet outlining the research and another A4 sheet listing up to 5 related publications.
Please send submissions to email@example.com before the deadline of 09.00hrs Monday 8th August 2016
Chronic liver disease patients who have suffered cervical spine trauma may have an increased risk of morbidity and mortality.
This was the novel finding by researchers at Brigham and Women's Hospital, Boston, who analysed patient records in the Massachusetts Statewide Inpatient Dataset (2003-2010).
Among 10,841 patients with cervical spine trauma, 117 had chronic liver disease. The rate of surgical intervention for cervical trauma was not significantly different between patients with and without chronic liver disease (odds ratio 0.82).
Mortality (odds ratio 2.12), failure to rescue (odds ratio 2.86), and complications (odds ratio 1.65) were all significantly increased for the patients with chronic liver disease in final adjusted models that controlled for differences in case-mix and whether a surgical procedure was performed. Final models explained approximately 72% of the variation in mortality and failure to rescue.
The effect of chronic liver disease on acute outcomes following cervical spine trauma. Bessey JT, Le H, Leonard DA et al. Spine J. 2016 Jun 8 [Epub ahead of print]
Two new studies suggest risk factors for hepatocellular carcinoma (HCC) in hepatitis patients include liver fibrosis, steatosis, diabetes and cirrhosis.
Japanese researchers cited liver fibrosis and steatosis as risk factors, regardless of past HBV infection and alcohol consumption (1).
Among HCC patients who underwent surgical resection at Shinshu University Hospital, Japan, between 1996 and 2012, 77 were negative for serum anti-HBV core/surface antibodies in addition to HBV surface antigen and anti-HCV antibody.
Advanced fibrosis and steatosis were detected in 64% and 60% of all patients. Approximately 85% of alcohol intake-positive patients had advanced fibrosis. Non-alcoholic fatty liver patients had the highest body mass index and prevalence of diabetes, but between 30% and 40% had none-to-mild fibrosis.
Cryptogenic patients (i.e., no alcohol intake or steatosis) exhibited the lowest incidence of accompanying hepatic inflammation/fibrosis but the largest tumour size. Recurrence/survival rates were comparable among the groups.
Meanwhile, Swedish researchers cited diabetes and cirrhosis as strong risk factors following successful treatment of HCV (2).
Among 399 patients with advanced liver disease successfully treated for HCV at Karolinska University Hospital, 17 developed HCC during 3366 person-years follow-up. The HCC incidence rates were 0.95 and 0.15 per 100 person years for patients with pre-treatment METAVIR F4 and F3, respectively.
Patients with pre-treatment cirrhosis and diabetes had a hazard ratio to develop HCC of 6.3, and an incidence rate of 7.9/100 person-years during the first two years of follow-up. The risk for HCC decreased significantly two years after SVR had been achieved.
1. Clinicopathological characteristics of non-B non-C hepatocellular carcinoma without past HBV infection. Kimura T, Kobayashi A, Tanaka N et al. Hepatol Res. 2016 Jun 11 [Epub ahead of print]
2. Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C. Hedenstierna M, Nangarhari A, Weiland O et al. Clin Infect Dis. 2016 Jun 9 [Epub ahead of print]
BASL School of Hepatology will be held at Nottingham University Park Campus over 2nd and 3rd July 2016
The event, including overnight accommodation, is free to attend for all medical qualified BASL members in training, restricted to 40 delegates
Friday 1st July
Evening Arrival at venue at delegates’ own leisure
Saturday 2nd July
09.30-09.40 Introduction and Welcome - Dr Martin James (Nottingham University Hospital)
09.40-10.10 Evolving biomarkers for the stratification of cirrhosis - Dr Neil Guha (Nottingham University Hospital)
Learning Objectives: Understanding novel methods for stratifying liver disease, including serum markers, TE and predictors of liver-related outcomes.
10.10-10.40 Detection of cirrhosis; are LFTs any good? - Dr Dave Harman (Oxford Deanery)
Learning Objectives: Challenging conventional strategies for detecting liver disease. Is finding asymptomatic, pre-clinical liver disease possible or worthwhile?
10.40-11.00 Panel interaction & questions
11.15-11.45 Treating alcoholic hepatitis; Beyond “STOPAH” study - Dr Andrew Austin (Royal Derby Hospitals)
Learning Objectives: Where does the STOPAH data lead us in clinical practice and exploring novel therapies for acute alcoholic hepatitis?
11.45-12.15 Achieving long term abstinence; Drugs, minimum unit pricing (MUP) or community support? - Mark Holmes; Alcohol long term conditions nurse (Nottingham)
Learning objectives: Understand the benefits and challenges of different strategies supporting long term abstinence in high risk drinkers.
12.15-12.45 Panel interaction & questions
13.30-14.00 Surveillance & treatment for varices - Dr Dhiraj Tripathi
Learning Objectives: Review of updated 2015 varices management guidelines.
14.00-14.30 Treating HCV in 2016 & beyond? - Professor Graham Foster
Learning objectives: The present and future treatment strategies for HCV infection in the UK. Can we afford not to treat?
14.30-15.00 Panel interaction & questions
15.15-15.45 Interventional Radiology (IR) & Hepatology: TACE, TIPS & tricks - Dr Richard O’ Neill
Learning Objectives: Understand and improve your interaction between hepatology and the interventional radiology team. Work up for “IR” (imaging, blood products, antibiotics and when to discuss).
15.45-16.30 Panel interaction & questions
19.00 Dinner in the Council Dining Room - 7pm Drinks Reception - 7.30pm Meal
Sunday 3rd July
Evidence based practice; consequences of cirrhosis -2
09.15-09.45 Treatment options in HCC - Dr Waleed Fateen (ACF Nottingham)
Learning Objectives: Understand curative and non-curative options for HCC management; can science help?
09.45-10.15 Symptomatic & palliative care in liver failure & HCC - Dr Ben Hudson (Bristol Severn Deanery Research Fellow)
Learning objectives: Predicting and preparing patients for liver failure and death. Who, where and how?
10.15-10.30 Panel interaction & questions
11.00-11.30 Stratifying and monitoring HCV - Professor Will Irving
Learning Objectives: Lessons from HCV UK and laboratory insights into monitoring and treating HCV infection
11.30-12.00 Treatment strategies for cirrhotic ascites - Dr Emilie Wilkes
Learning objectives: Novel approaches to patient and nurse-led management of cirrhotic ascites
12.00-12.15 Panel interaction & questions
12.15 -13.00 Clinical cases, summary and close - Dr Martin James
If you have any queries please contact firstname.lastname@example.org or Tel: 01543 442154.
Venue: The Royal Free Hospital, London
This is the 2nd in a series of International meetings with the Sheila Sherlock brand aimed at renovating the tradition of the periodic updates introduced by Dame Sheila Sherlock at the Royal Free Hospital. This new series is dedicated to current fundamental themes in Hepatology that will be presented and discussed by the Royal Free Liver Specialists together with some of the most renown International speakers.
Full programme information can be downloaded here - Download Programme 1-3 Sept 2016.pdf .
To find out more information and how to Register for the event click > here.
Please contact Lynn Knight if you have any questions - email@example.com.
Venue: Manchester Central, Manchester
The School of Transplantation will take place on Tuesday 6th September in parallel to the British Liver Transplant Group (BLTG) meeting, which both run prior to the start of the main BASL Annual Meeting, which starts on the afternoon of Wednesday 7th September.
Delegates will be encouraged to attend this day along with the BLTG themed sessions on the morning of Wednesday 7th September before the Annual Meeting.
Please click here to view the 'draft' programme Download Draft Transplant School 2016_Programme Published.pdf.
To book for the event click > here.
Venue - Manchester Central
The Chair of the BLTG, Professor Darius Mirza would like to invite you to the third meeting of the BLTG (British Liver Transplant Group).
As an affiliate of BASL, the BTLG has built on the role of the UK and Ireland Annual Meeting and will integrate the meetings previously organised by each individual transplant centre to offer a central stage for those operating in or with a strong interest in the field of liver transplantation.
This meeting will be linked to the BLTG Sessions and Williams-Calne Lecture within the BASL Annual Meeting programme on Wednesday 7th September; 08.30-13.00.
We hope that you will be present at this meeting, which will be attended by both eminent UK and international speakers, including Professor Mike Lucey, University of Wisconsin School of Medicine and Public Health, who will also deliver the distinguished Williams-Calne lecture.
REGISTRATION - all of the details including the programme can be found on the BASL / BLTG Annual Meeting website by clicking > here.
Andy Burroughs Young Investigator Award - submit your application for the Andy Burroughs Young Investigator Award - deadline 9:00 Monday 8th August - read more on the BASL / BLTG Annual Meeting website > here.
Registration and Abstract Submission is now OPEN
Venue: Manchester Central, Manchester
VISIT THE BASL Annual Meeting 2016 website to find out Programme Information, to Submit an Abstract and to Register - CLICK HERE.
The BASL Annual Meeting is the highlight of the BASL calendar and the main liver meeting in the UK. This year we hope to attract in excess of 500 delegates, bringing together clinicians, nurses, scientists and all those interested in liver disease.
Eminent UK and overseas speakers converge to deliver an informative and exciting meeting over three days, which for September 2016 will take place at Manchester Central.
ABSTRACTS - now closed.
A preview of the programme can also be found here Download Annual Meeting Programme.pdf
This symposium is the leading International conference focused on the management of hepatitis among substance users. It is organised by the International Network for Hepatitis in Substance Users (INHSU). In 2015, INHSU decided to move to an annual symposium to keep pace with the rapid development of new therapies and exciting new research on HCV care among people who inject drugs. Hence, the 2016 INHSU symposium will be held in Oslo, Norway.
The International Symposium on Hepatitis in Substance Users attracts delegates including health professionals (doctors, nurses and allied health), researchers, community organisations, people who use drugs and policy makers.
Abstract submission is now open. Submit your abstract before Friday 22 April 2016.
For further information and to register click here.
Coimbra Liver Transplantation Conference - Coagulation Liver Disease and Liver Transplant Facts and Controversies
Event Content - Monothematic meeting will cover a variety of concepts in liver and coagulation, highlighting management before, during and after liver transplant.
Venue - Coimbra Paediatric Hospital Auditorium - Coimbra Hospital and University Centre
To find out more information click here.
The Royal College of Physicians of Edinburgh (RCPE) and the Society for Acute Medicine (SAM) are delighted to be bringing you the most ambitious international programme on the past, present and future of medicine. This two-day conference will combine the historical aspects of medicine with a look to the future for healthcare across a broad range of clinical topics.
Venue: The Edinburgh International Conference Centre
Abstracts: Deadline 10 July 2016
For further information view here Download Edinburgh International Conference of Medicine Past Present and Future.pdf
You will be able to design your own agenda for the conference, choosing from a comprehensive range of over 35 parallel sessions covering over 15 specialties, ranging from acute medicine, cardiology, care of the older patient, diabetes, neurology and respiratory to health & wellbeing, maternal medicine and patient involvement.
This conference is open to all healthcare professionals at all stages of their careers and is a great opportunity to keep up to date with the latest clinical research, opinions and innovations in medicine, as well as building your network.
The conference has been approved for 12 CPD points.
Full details on abstract submission, registration and programme are available by clicking here.
Join BASL Ward Membership Today - £100 per annum for up to 5 members per ward.
Ward membership benefits include; access to the Nurse e-learning toolkits on the BASL website, reduced fees at BASL Events including the Nurses Day at the Annual Meeting in September.
To find out how to apply click here.
BASL Committee Post Vacancies:-
- Services Commitee Chair
- Paediatric Representative
Apply before 20th June. Click here for more information.
The BASL Nurse Toolkits were developed following conversations with nurse specialists. These and a later email survey identified training needs to help nurses meet the liver nurse competencies. To access the Learning Toolkits sign in as a BASL Member and click on Manage Account